一直以来，兰州高新区始终将营商环境建设作为重中之重，兰州高新区营商环境取得了长足进步。良好 的营商环境不仅增强了企业的发展信心，也促进了招商引资的实效提升。今年以来，已有两家优质企业 相继入驻园区，正是高新区营商环境持续优化的生动体现。 定远派出所、连搭派出所及消防大队相关负责人一致表示，服务企业、护航发展是职责所在，将继续秉 持"便企、利企、护企"宗旨，不断提升警务与消防服务水平，为高新区企业安全生产、稳定运营营造更 加安全、有序的环境。 政企同心，其利断金。此次慰问活动既是企业对政务服务与安全保障的暖心回馈，更是高新区政企良性 互动、协同发展的生动写照。下一步，兰州高新区将继续深化政企联动，持续优化营商环境，全力破解 企业发展难题，让更多像王老吉这样的优质企业在高新沃土上安心创业、顺心发展，共同谱写区域高质 量发展新篇章。（完） 中新网甘肃新闻1月20日电 1月18日，王老吉大健康产业（兰州）有限公司向兰州高新区定远派出所、 连搭派出所及高新区消防大队赠送慰问品，以此表达对一线警务与消防人员长期以来倾力服务企业、护 航发展的诚挚感谢。兰州高新区党工委、管委会相关负责人出席活动。 活动中，王老吉大健康产业（ ...

1月19日，广州市第十六届人民代表大会第六次会议开幕，广州市市长孙志洋向大会作政府工作报告。 今年的市政府工作报告在延续"12218"现代化产业体系总体框架下，首次极为明确地提出聚焦人工智 能、海洋经济、生物医药三大产业，并将其分别定位为"制胜赛道""战略赛道"和"决胜赛道"。 这在往年政府工作报告中鲜有出现，背后则是广州经济发展进入新阶段的必然逻辑。过去五年，广州固 定资产投资稳居全省第一，社会消费品零售总额跨越1.1万亿元，商品出口增速领跑全省。自然指数科 研城市排名升至全球第六、GaWC世界城市名册跻身全球一线城市行列。 这些指标变化揭示了一个趋势：广州的竞争力，正在从传统要素驱动，加速转向科技创新与高端产业驱 动。6个产值超千亿元的先进制造业集群、48款备案人工智能大模型、超过2200亿元的生物医药产业营 收，是广州实力的一角；而报告提到的"动能转换接续还需提速""科技成果转化存在卡点"则指明了未来 还需发力的方向。 强调发展人工智能、海洋产业、生物医药三大产业，体现了广州在国家战略与自身优势交叉点上寻找增 长极的系统思维，也是城市对发展质量与动能的更深层次要求。在"十五五"开局之年2026年，广州将 ...

转自：扬子晚报 1月18日，有广州市民发帖称，在白云山景区徒步时，在一家餐馆附近的山上不慎踩中捕兽夹。据其描 述，夹具无锯齿，脚掌未受重伤，但越挣扎夹得越紧，导致脚部血流不畅，几分钟内便感到发麻，后经 人帮忙解开。1月19日，记者致电广州市白云山风景名胜区管理局，工作人员表示，景区内严禁放置捕 兽夹，该市民反映的位置确属景区范围，目前正在调查核实。 广州市民发帖称，自己在白云山景区徒步时被捕兽夹夹住。 该帖配图显示，一个人的右脚脚掌被捕兽夹夹住。帖子引发网友热议，有人指出"在公共景点放置捕兽 夹完全违法"，有人建议报警，"既为个人安全，也为他人着想"。也有网友担心山上动物安全，"白云山 有许多猫和野生动物，不敢想象它们被夹住的后果"。发帖人随后在评论区回应称，当日自己在山中见 到鹿和松鼠等动物。 来源 | 上游新闻 1月19日，记者联系到发帖人。据其回忆，事件发生在18日徒步期间。当时正按"画猫"（徒步轨迹在地 图上形似一只猫）路线行走，因稍微有点迷路未注意脚下，误踩捕兽夹。解开捕兽夹后，担心附近还有 其他陷阱，未多停留便直接下山。对方表示，事后才意识到在景区设置捕兽夹属违法行为，但当时只想 着尽快离开。"因 ...

生物医药产业是广东省、广州市聚力打造的战略性支柱产业。广州正全力冲刺五年内建成4000亿级生物 医药与健康产业集群的目标，广州已集聚超6500家生物医药企业，形成完整成熟的产业生态。南都湾财 社记者从广药集团获悉，近日，由广药集团等3家企业牵头成立的广州市药械产品出口综合服务平台正 式揭牌。 作为广州市生物产业联盟新一届理事长，广药集团董事长李小军表示，广药在"十五五"期间将锚定"再 造一个新广药"目标，全面实施"现代化、数字化、科技化、国际化" 战略，通过牵头建设国转中心生物 医药分中心、发力核药产业等举措攻坚四大前沿赛道。 据了解，由广药集团等3家企业联合牵头成立广州市药械产品出口综合服务平台，旨在整合产业优质资 源，为广州市药械产品出口提供一站式专业服务。 广药集团有关负责人表示，平台的落地将为广州生物医药产业创新成果转化及国际化布局注入新动能， 有效助力企业拓宽海外市场通道，加速产业全球化步伐。 为了在"十五五"期间加速布局核药新赛道，白云山稀核健康公司与纳斯达克上市企业GE医疗签署了产 学研转化中心业务合作协议。根据协议，双方将与医院共建产学研转化实验室。 广药集团副总经理程洪进表示，白云山稀核健康 ...

Investment Rating - The report indicates a positive investment outlook for the body care industry, projecting a compound annual growth rate (CAGR) of 6.4% from 2024 to 2028, with the market expected to exceed 37.8 billion yuan by 2028 [13]. Core Insights - The body care market in China is experiencing significant growth, driven by increasing consumer demand for personal health and care products, indicating long-term growth potential and innovation opportunities [13]. - Regulatory upgrades are favoring leading companies in the industry, shifting competition from marketing to research and development, benefiting firms with compliance capabilities and technological reserves [15]. - E-commerce platforms are showing divergent trends, with Douyin (TikTok) experiencing a robust sales increase of 93% year-on-year, while Taobao's sales remain stagnant [18]. Summary by Sections Industry Macro Market Research - The body care industry is defined as a range of personal care products designed to clean, nourish, protect, and improve the health of skin on areas other than the face and hands [11]. - The market size for body care products is projected to grow significantly, with a forecasted CAGR of 6.4% from 2024 to 2028, reaching over 37.8 billion yuan [13]. Online Industry Trend Overview - As of September 2025, the combined sales on Taobao and Douyin reached 9.55 billion yuan, with Douyin's sales growing significantly due to its high volume and mid-to-low price strategy [18]. - Taobao's body care category saw a slight growth of 2.2%, with body lotion/cream being the top category, while body care sets and essences showed substantial growth rates of 44% and 151%, respectively [21]. Leading Brand Analysis on Douyin - Douyin's body care sales reached 5.78 billion yuan, significantly outperforming Taobao, with a strong emphasis on promotional events driving sales spikes [41]. - The leading brands on Douyin include domestic brands like 卡唯朵 (Kawai Duo) and 半亩花田 (Half Mu Flower Field), which dominate the market with high sales volumes [28]. Brand Analysis - Baiyunshan - Baiyunshan, a core subsidiary of Guangzhou Pharmaceutical Group, has positioned itself as a leader in the health and wellness sector, leveraging traditional Chinese medicine and modern technology [38]. - The brand's sales on Douyin have shown explosive growth, particularly during major promotional events, indicating a strong alignment with the platform's consumer engagement strategies [41].

Group 1 - The stock of Baiyunshan closed down by 0.79% on January 14, with a closing price of 25.10 yuan [1] - A block trade occurred with a total volume of 97,200 shares and a transaction amount of 2.4397 million yuan, with a premium rate of 0.00% [1] - The buyer and seller for the block trade were both from Dongfang Securities Co., Ltd., Shanghai Huangpu District Zhonghua Road Securities Business Department [1] Group 2 - In the last three months, Baiyunshan has recorded a total of three block trades, with a cumulative transaction amount of 11.7939 million yuan [1] - Over the past five trading days, the stock has declined by 1.34%, with a total net outflow of 415 million yuan from main funds [1]

1月14日，白云山大宗交易成交9.72万股，成交额243.97万元，占当日总成交额的0.44%，成交价25.1元，较市场收盘价25.1元持平。 | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-14 | | 600332 | 25.1 243.97 | 9.72 | 东方证券股份直限 | 东方证券股省包限 | | ...

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw materials industry, indicating a steady increase in production and market dynamics from 2025 to 2032 [1] Industry Summary - In November 2025, China's chemical pharmaceutical raw material production reached 331,000 tons, reflecting a year-on-year growth of 1.5% [1] - From January to November 2025, the cumulative production of chemical pharmaceutical raw materials in China was 3,358,000 tons, with a cumulative growth of 1.8% [1] - The report by Zhiyan Consulting provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China, projecting future trends from 2026 to 2032 [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1]

Core Viewpoint - The company emphasizes that its stock price fluctuations are influenced by multiple factors and reassures that its production and operations are normal, with no undisclosed significant matters [1] Group 1: Company Operations - The company is focused on enhancing quality and efficiency in its core business [1] - There will be an increased emphasis on innovation and research and development of core products [1] Group 2: Shareholder Engagement - The company plans to continue rewarding shareholders through cash dividends [1] - It aims to strengthen communication with investors through roadshows, performance briefings, and research receptions to convey company value and seek better investment returns [1]

证券日报网讯 1月12日，白云山在互动平台回答投资者提问时表示，公司目前生产经营正常。公司股价 波动受多方面因素影响，公司不存在应披露而未披露的重大事项。 （文章来源：证券日报） ...